Capricor Therapeutics to Hold First Quarter 2015 Business Update and Financial Results Conference Call on May 12, 2015 at 4:30 p.m. EDT
May 05, 2015 16:05 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 5, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
April 22, 2015 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 22, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure
April 08, 2015 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 8, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure
March 31, 2015 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 31, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25, 2015 in New York
March 23, 2015 08:05 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 23, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Therapeutics Reports Fourth Quarter and Full Year 2014 Financial & Business Highlights
March 18, 2015 16:05 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 18, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT
March 12, 2015 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 12, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Therapeutics to Present at the 27th Annual ROTH Conference
March 10, 2015 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 10, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular...
Capricor Announces Enrollment of Its Phase II Clinical Trial for Cenderitide to Treat Heart Failure
March 05, 2015 09:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 5, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...
Capricor Therapeutics Announces Uplisting to NASDAQ Capital Market
March 05, 2015 08:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, March 5, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (OTCQB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases,...